Literature DB >> 23478441

Regulation of the CRL4(Cdt2) ubiquitin ligase and cell-cycle exit by the SCF(Fbxo11) ubiquitin ligase.

Mario Rossi1, Shanshan Duan, Yeon-Tae Jeong, Moritz Horn, Anita Saraf, Laurence Florens, Michael P Washburn, Adam Antebi, Michele Pagano.   

Abstract

F-box proteins and DCAF proteins are the substrate binding subunits of the Skp1-Cul1-F-box protein (SCF) and Cul4-RING protein ligase (CRL4) ubiquitin ligase complexes, respectively. Using affinity purification and mass spectrometry, we determined that the F-box protein FBXO11 interacts with CDT2, a DCAF protein that controls cell-cycle progression, and recruits CDT2 to the SCF(FBXO11)complex to promote its proteasomal degradation. In contrast to most SCF substrates, which exhibit phosphodegron-dependent binding to F-box proteins, CDK-mediated phosphorylation of Thr464 present in the CDT2 degron inhibits recognition by FBXO11. Finally, our results show that the functional interaction between FBXO11 and CDT2 is evolutionary conserved from worms to humans and plays an important role in regulating the timing of cell-cycle exit.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23478441      PMCID: PMC3624904          DOI: 10.1016/j.molcel.2013.02.004

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  35 in total

1.  Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase.

Authors:  Tarig Bashir; N Valerio Dorrello; Virginia Amador; Daniele Guardavaccaro; Michele Pagano
Journal:  Nature       Date:  2004-03-11       Impact factor: 49.962

2.  The mutational landscape of head and neck squamous cell carcinoma.

Authors:  Nicolas Stransky; Ann Marie Egloff; Aaron D Tward; Aleksandar D Kostic; Kristian Cibulskis; Andrey Sivachenko; Gregory V Kryukov; Michael S Lawrence; Carrie Sougnez; Aaron McKenna; Erica Shefler; Alex H Ramos; Petar Stojanov; Scott L Carter; Douglas Voet; Maria L Cortés; Daniel Auclair; Michael F Berger; Gordon Saksena; Candace Guiducci; Robert C Onofrio; Melissa Parkin; Marjorie Romkes; Joel L Weissfeld; Raja R Seethala; Lin Wang; Claudia Rangel-Escareño; Juan Carlos Fernandez-Lopez; Alfredo Hidalgo-Miranda; Jorge Melendez-Zajgla; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub; Levi A Garraway; Jennifer R Grandis
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

3.  Frequent pathway mutations of splicing machinery in myelodysplasia.

Authors:  Kenichi Yoshida; Masashi Sanada; Yuichi Shiraishi; Daniel Nowak; Yasunobu Nagata; Ryo Yamamoto; Yusuke Sato; Aiko Sato-Otsubo; Ayana Kon; Masao Nagasaki; George Chalkidis; Yutaka Suzuki; Masashi Shiosaka; Ryoichiro Kawahata; Tomoyuki Yamaguchi; Makoto Otsu; Naoshi Obara; Mamiko Sakata-Yanagimoto; Ken Ishiyama; Hiraku Mori; Florian Nolte; Wolf-Karsten Hofmann; Shuichi Miyawaki; Sumio Sugano; Claudia Haferlach; H Phillip Koeffler; Lee-Yung Shih; Torsten Haferlach; Shigeru Chiba; Hiromitsu Nakauchi; Satoru Miyano; Seishi Ogawa
Journal:  Nature       Date:  2011-09-11       Impact factor: 49.962

Review 4.  CRL4Cdt2: master coordinator of cell cycle progression and genome stability.

Authors:  Tarek Abbas; Anindya Dutta
Journal:  Cell Cycle       Date:  2011-01-15       Impact factor: 4.534

5.  DRE-1: an evolutionarily conserved F box protein that regulates C. elegans developmental age.

Authors:  Nicole Fielenbach; Daniele Guardavaccaro; Kerstin Neubert; Tammy Chan; Dongling Li; Qin Feng; Harald Hutter; Michele Pagano; Adam Antebi
Journal:  Dev Cell       Date:  2007-03       Impact factor: 12.270

6.  Diverse somatic mutation patterns and pathway alterations in human cancers.

Authors:  Zhengyan Kan; Bijay S Jaiswal; Jeremy Stinson; Vasantharajan Janakiraman; Deepali Bhatt; Howard M Stern; Peng Yue; Peter M Haverty; Richard Bourgon; Jianbiao Zheng; Martin Moorhead; Subhra Chaudhuri; Lynn P Tomsho; Brock A Peters; Kanan Pujara; Shaun Cordes; David P Davis; Victoria E H Carlton; Wenlin Yuan; Li Li; Weiru Wang; Charles Eigenbrot; Joshua S Kaminker; David A Eberhard; Paul Waring; Stephan C Schuster; Zora Modrusan; Zemin Zhang; David Stokoe; Frederic J de Sauvage; Malek Faham; Somasekar Seshagiri
Journal:  Nature       Date:  2010-07-28       Impact factor: 49.962

7.  SCF(Cyclin F) controls centrosome homeostasis and mitotic fidelity through CP110 degradation.

Authors:  Vincenzo D'Angiolella; Valerio Donato; Sangeetha Vijayakumar; Anita Saraf; Laurence Florens; Michael P Washburn; Brian Dynlacht; Michele Pagano
Journal:  Nature       Date:  2010-07-01       Impact factor: 49.962

8.  Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex.

Authors:  Wenyi Wei; Nagi G Ayad; Yong Wan; Guo-Jun Zhang; Marc W Kirschner; William G Kaelin
Journal:  Nature       Date:  2004-03-11       Impact factor: 49.962

9.  FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.

Authors:  Shanshan Duan; Lukas Cermak; Julia K Pagan; Mario Rossi; Cinzia Martinengo; Paola Francia di Celle; Bjoern Chapuy; Margaret Shipp; Roberto Chiarle; Michele Pagano
Journal:  Nature       Date:  2012-01-05       Impact factor: 49.962

10.  Association of the FBXO11 gene with chronic otitis media with effusion and recurrent otitis media: the Minnesota COME/ROM Family Study.

Authors:  Fernando Segade; Kathleen A Daly; Dax Allred; Pamela J Hicks; Miranda Cox; Mark Brown; Rachel E Hardisty-Hughes; Steve D M Brown; Stephen S Rich; Donald W Bowden
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2006-07
View more
  36 in total

Review 1.  SCF ubiquitin ligase-targeted therapies.

Authors:  Jeffrey R Skaar; Julia K Pagan; Michele Pagano
Journal:  Nat Rev Drug Discov       Date:  2014-11-14       Impact factor: 84.694

2.  14-3-3 proteins play a role in the cell cycle by shielding cdt2 from ubiquitin-mediated degradation.

Authors:  Ashraf Dar; David Wu; Nicholas Lee; Etsuko Shibata; Anindya Dutta
Journal:  Mol Cell Biol       Date:  2014-08-25       Impact factor: 4.272

Review 3.  Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins.

Authors:  Nana Zheng; Zhiwei Wang; Wenyi Wei
Journal:  Int J Biochem Cell Biol       Date:  2016-02-06       Impact factor: 5.085

4.  FBXO11 promotes ubiquitination of the Snail family of transcription factors in cancer progression and epidermal development.

Authors:  Yue Jin; Anitha K Shenoy; Samuel Doernberg; Hao Chen; Huacheng Luo; Huangxuan Shen; Tong Lin; Miriam Tarrash; Qingsong Cai; Xin Hu; Ryan Fiske; Ting Chen; Lizi Wu; Kamal A Mohammed; Veerle Rottiers; Siu Sylvia Lee; Jianrong Lu
Journal:  Cancer Lett       Date:  2015-03-28       Impact factor: 8.679

Review 5.  Deregulation of F-box proteins and its consequence on cancer development, progression and metastasis.

Authors:  Jinho Heo; Rebeka Eki; Tarek Abbas
Journal:  Semin Cancer Biol       Date:  2015-09-30       Impact factor: 15.707

Review 6.  MicroRNA regulation of F-box proteins and its role in cancer.

Authors:  Zhao-Hui Wu; Lawrence M Pfeffer
Journal:  Semin Cancer Biol       Date:  2015-10-01       Impact factor: 15.707

7.  DRE-1/FBXO11-dependent degradation of BLMP-1/BLIMP-1 governs C. elegans developmental timing and maturation.

Authors:  Moritz Horn; Christoph Geisen; Lukas Cermak; Ben Becker; Shuhei Nakamura; Corinna Klein; Michele Pagano; Adam Antebi
Journal:  Dev Cell       Date:  2014-03-06       Impact factor: 12.270

Review 8.  Small molecule therapeutics targeting F-box proteins in cancer.

Authors:  Yuan Liu; Rama K Mallampalli
Journal:  Semin Cancer Biol       Date:  2015-09-30       Impact factor: 15.707

Review 9.  RING-type E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination.

Authors:  Meredith B Metzger; Jonathan N Pruneda; Rachel E Klevit; Allan M Weissman
Journal:  Biochim Biophys Acta       Date:  2013-06-06

Review 10.  Roles of F-box proteins in cancer.

Authors:  Zhiwei Wang; Pengda Liu; Hiroyuki Inuzuka; Wenyi Wei
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.